SEATTLE, Feb. 7, 2017 -- Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced today that it has entered into service agreements with Camargo Pharmaceutical Services, LLC. Camargo will be providing end-to-end regulatory consulting and strategic development services for Impel's pipeline of drug-device combination products built...

When: January 10, 2016 – January 11, 2016 (all-day) Where: San Francisco, CA, USA Who: Impel CEO, John Hoekman will be attending the 35th annual JPM Healthcare Conference ...

Seattle May 4, 2016 -- Development of neurological and mental health drugs often requires pre-clinical testing in multiple pre-clinical models to demonstrate efficacy and safety and to elucidate mechanisms. Drug delivery to the central nervous system (CNS) to target neurological diseases is particularly problematic because the blood-brain barrier (BBB) prevents...